Delamanid tuberculosis treatment

Delamanid is a dihydro-imidazooxazole that exhibits excellent activity against Mycobacterium tuberculosis both in vitro and in murine tuberculosis models. It has also recently been reported that when added to an optimized background protocol, it can improve sputum culture conversion rates in patients with MDR-TB. Although generally well tolerated, delamanid has been associated with QT prolongation.

Tuberculosis (TB), caused by Mycobacterium tuberculosis(MTB), is the leading cause of death from infectious diseases worldwide. Widespread and increasing resistance to TB drugs is reducing treatment effectiveness and jeopardizing TB control. Delamanidhas potent activity against replicating, dormant and intracellular Mycobacterium tuberculosis and is bactericidal in mouse and guinea pig models of tuberculosis. Published susceptibility testing results of clinical isolates from 744 treatment-naïve patients with delamanid disease indicate that the rate of natural resistance to delamanid disease is very low (1.3%). Delamanidis metabolized primarily by albumin in serum and to a much lesser extent by cytochromeP.

The original drug Delamani has been launched in China and is included in the scope of Class B medical insurance. Reimbursement is limited to patients with multi-drug-resistant tuberculosis. Specifications The price of each box of 50mg*60 tablets may be around RMB 6,000. The price of the Russian version of the original drug Dramani, 50mg*48 tablets, sold overseas may be around RMB 1,000-2,000 per box (the price may fluctuate due to the exchange rate). There is currently no generic version of Dramani available on the market. For more drug information and specific prices, please consult Yaode’s medical consultant.